Table 1.
Compound | α 1 | α 2 | α 3 | α 5 | α 1/α 2-ratio | ||||
---|---|---|---|---|---|---|---|---|---|
K i (nM) | Efficacy° (%) | K i (nM) | Efficacy°(%) | K i (nM) | Efficacy°(%) | K i (nM) | Efficacy° (%) | ||
TPA023* [26] | 0.27 | 0# | 0.31 | 11 | 0.19 | 21 | 0.41 | 5 | 0 |
TPACMP2* [13] | 0.22 | 18 | 0.40 | 23 | 0.21 | 45 | 0.23 | 18 | 0.78 |
SL65.1498# [28] | 17 | 45 | 73 | 115 | 80 | 83 | 215 | 48 | 0.39 |
Zolpidem | 20 [29] | 75§ [30] | 400 [29] | 78§ [30] | 400 [29] | 80§ | 5000 [29] | 9§ [30] | 0.96 |
°Relative efficacy is defined as the extent of the potentiation of GABA-A EC20-equivalent current produced by the compound compared to that produced by a nonselective full agonist (chlordiazepoxide/diazepam).
*Mean values of 3 experiments in Xenopus oocytes with human recombinant αβ3γ2 receptors; efficacy relative to chlordiazepoxide.
#Mean values of 3 experiments in hek293 cells with recombinant rat receptors αβ2γ2; efficacy relative to chlordiazepoxide.
§Mean values of 3 experiments in Xenopus oocytes with human recombinant αβ2γ2 receptor; efficacy relative to diazepam.